Patents by Inventor Hal GERBER

Hal GERBER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20230414627
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: April 26, 2023
    Publication date: December 28, 2023
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20230321112
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: December 9, 2022
    Publication date: October 12, 2023
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG
  • METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
    Publication number: 20220211711
    Abstract: Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
    Type: Application
    Filed: February 8, 2022
    Publication date: July 7, 2022
    Inventors: Alexis HOWERTON, Hal GERBER
  • Corticotropin releasing factor receptor antagonists
    Patent number: 11351177
    Abstract: The present invention provides novel pharmaceutical compositions comprising-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 7, 2022
    Assignee: Spruce Biosciences, Inc.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Corticotropin releasing factor receptor antagonists
    Patent number: 11344557
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 31, 2022
    Assignee: Spruce Biosciences, Inc.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20220143037
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: January 27, 2022
    Publication date: May 12, 2022
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG
  • Corticotropin releasing factor receptor antagonists
    Patent number: 11311549
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: April 26, 2022
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Methods for treating testicular and ovarian adrenal rest tumors
    Patent number: 11304950
    Abstract: Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: April 19, 2022
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20210361664
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: August 14, 2018
    Publication date: November 25, 2021
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20210322431
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: June 25, 2021
    Publication date: October 21, 2021
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20210322430
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: June 25, 2021
    Publication date: October 21, 2021
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG
  • Corticotropin releasing factor receptor antagonists
    Patent number: 11007201
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 18, 2021
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20210137935
    Abstract: The present invention provides novel pharmaceutical compositions comprising 3-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: August 14, 2018
    Publication date: May 13, 2021
    Applicant: Spruce Biosciences, Inc.
    Inventors: Alexis HOWERTON, Hal GERBER, Sami KARABORNI
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20210038609
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: October 22, 2020
    Publication date: February 11, 2021
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG
  • METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
    Publication number: 20210038604
    Abstract: Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
    Type: Application
    Filed: October 27, 2020
    Publication date: February 11, 2021
    Inventors: Alexis HOWERTON, Hal GERBER
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20210015827
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: October 5, 2020
    Publication date: January 21, 2021
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG
  • Corticotropin releasing factor receptor antagonists
    Patent number: 10849908
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 1, 2020
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20200255436
    Abstract: The present disclosure provides forms of CRF antagonists and methods using such CRF antagonists for treating diseases.
    Type: Application
    Filed: February 11, 2020
    Publication date: August 13, 2020
    Inventors: Alexis HOWERTON, Hal GERBER, Sami KARABORNI, Sangita GHOSH
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20190262349
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: April 18, 2019
    Publication date: August 29, 2019
    Inventors: Alexis HOWERTON, Hal GERBER, Michael HUANG